Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=38734884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600467(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/262,113external-prioritypatent/US20060189635A1/en
Application filedfiledCritical
Publication of GT200600467ApublicationCriticalpatent/GT200600467A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
SE REVELAN MÉTODOS Y FORMAS DE DOSIFICACIÓN QUE COMPRENDEN DERIVADOS DE BENZISOXAZOL. MÁS PARTICULARMENTE, SE REVELAN MÉTODOS, FORMAS DE DOSIFICACIÓN, Y NUEVOS USOS DE DERIVADOS DE BENZISOXAZOL QUE PROVEEN EFICACIA MEJORADA CUANDO SE UTILIZAN EN EL TRATAMIENTO DE LA ESQUIZOFRENIA Y/O DE LA MANÍA BIPOLAR. T2006METHODS AND DOSAGE FORMS THAT INCLUDE DERIVATIVES OF BENZISOXAZOL ARE DISCLOSED. MORE PARTICULARLY, METHODS, DOSAGE METHODS, AND NEW USES OF BENZISOXAZOL DERIVATIVES THAT PROVIDE IMPROVED EFFECTIVENESS WHEN USED IN THE TREATMENT OF SCHIZOPHRENIA AND / OR BIPOLAR MANIA ARE DISCLOSED. T2006
GT200600467A2005-10-192006-10-19
METHODS AND DOSAGE FORMS OF BENZISOXAZOL DERIVATIVES WITH BETTER EFFECTIVENESS
GT200600467A
(en)
Use of compound genz-112638 (eliglustat), glucosylceramide synthase inhibitor, in the treatment of gaucher disease and fabry disease (divisional application 201201348).
MACROCICLOS COMPOUNDS, SELECTIVE INHIBITORS OF SERIOAPROTEASA VIEW COAGULATION FACTOR; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF A THROMBOEMBOLIC DISORDER.
COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
Compounds derived from 17-beta-cyano-18 alpha-homo-19-nor-androst-4-eno; presenting gestagenic and antimineralcorticoid activity; pharmaceutical composition; and use in the treatment of pre-peri-and postmenopausal disorders and premenstrual disorders.
Compounds derived from substituted phenylamino-benzene; Preparation method; pharmaceutical composition; farm kit; and use of said compounds in the treatment of cancer.
COMPOUNDS DERIVED FROM OCTAHIDRO-PIRROLO [3,4-C] PIRROL; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND USE OF THE COMPOUND IN THE TREATMENT OF HIV, AIDS OR ARC.
Compounds derived from 6- (4-benzylpiperazin-1-yl) pyrimidin-4-one, modulators of the enzyme stearoyl-coa-desaturase 1; preparation procedure; pharmaceutical composition; and use in the treatment and prophylaxis of obesity.
Pharmaceutical combination comprising the compound 2- {2 - [(2s) -2-methyl-2,3-dihydro-1h-indol-1-yl] -2-oxoethyl} -6- (morpholin-4-yl) pyrimidin -4- (3h) -one and at least one inhibitor of the mapk pathway; pharmaceutical composition; pharmaceutical kit; its use in the treatment of cancer.